Annovis Bio, Inc. ANVS

Annovis Bio inks a collaboration with Weave Bio to use an AI regulatory platform for drafting and managing its NDA ahead of a 6-month top-line readout from its Phase 3 Alzheimer's trial. Annovis will keep sole responsibility for content, verification and FDA submission. The aim is to have most of the NDA ready before the data readout to shorten the path to filing. Weave will assist with drafting, review and organization, freeing regulatory staff for scientific strategy. The deal accompanies the company's completion of enrollment in the pivotal Phase 3 AD trial (NCT06709014), which enrolled 862 biomarker-confirmed patients, surpassing the target of 760. The team expects the database lock in December 2026 and top-line symptomatic data in March 2027. The arrangement follows FDA AI guidance from January 2025. AI-assisted NDA prep can speed filing and support investor confidence ahead of pivotal trial data.

Annovis Bio sets March 2027 target for Alzheimer's data readout while advancing rolling NDA preparations. Targeted 2027 readout and NDA prep indicate pivotal clinical and regulatory progress for core Alzheimer's program.

Annovis Bio released corporate updates along with its second quarter 2026 financial results. Quarterly financial results and corporate updates can shift investor views on operational progress and near-term prospects.

Annovis Bio enrolls over 850 patients for its next Alzheimer's disease trial. Reaching over 850 enrolled patients marks major clinical progress for Annovis Bio's lead Alzheimer's program.

Annovis Bio reaches full enrollment in pivotal Phase 3 trial of Buntanetap for early Alzheimer’s disease. Full Phase 3 enrollment marks key clinical milestone advancing Buntanetap toward potential approval and revenue.

Annovis Bio priced a $15.0 million public offering of common stock and accompanying warrants. Offering supplies capital for operations while diluting existing shares.

Annovis Bio, Inc. (ANVS) launches a proposed public offering of common stock and accompanying warrants. Proposed stock offering raises capital while diluting shares and pressuring near-term valuation.

Annovis Bio, Inc. (ANVS) provided corporate updates and reported first quarter 2026 financial results. Corporate updates combined with Q1 2026 financial results are likely to moderately influence investor sentiment and short-term stock performance.

Annovis Bio, Inc. (ANVS) published results from its Phase 2/3 Alzheimer's disease clinical trial in a Nature Portfolio journal. Phase 2/3 Alzheimer's trial results in a top-tier Nature journal could transform ANVS's position in the neurodegeneration market.

Annovis Bio, Inc. (ANVS) closed a $10 million offering, extending its cash runway through the Phase 3 Alzheimer's Disease 6-month NDA submission. Securing $10 million extends cash runway to a pivotal Phase 3 Alzheimer's NDA submission, enabling key clinical progress without immediate dilution risks.

Annovis Bio, Inc. (ANVS) announced a $10 million underwritten public offering of common stock and accompanying warrants to raise capital. $10 million capital raise extends financial runway for clinical development but dilutes shareholder equity, moderately impacting performance.

Annovis Bio, Inc. (ANVS) secured a U.S. patent for Buntanetap to prevent and treat neurological injuries caused by brain infections. U.S. patent for Buntanetap in brain infection neurological injuries bolsters Annovis Bio's IP protection and expands treatment applications beyond neurodegeneration.

Annovis Bio, Inc. (ANVS) partners with NeuroRPM to deploy AI-powered digital biomarker technology in a Parkinson's disease study, aiming to enhance remote patient monitoring and data collection for better clinical outcomes. Partnership integrates cutting-edge AI biomarkers into Parkinson's study, strengthening clinical pipeline and competitive edge in neurodegenerative therapies.

NeuroRPM will deploy AI-enabled digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial. AI integration into Parkinson's trial boosts Annovis Bio's data capabilities and investor appeal.

Annovis Bio, Inc. (ANVS) provides corporate updates and reports fiscal year 2025 financial results. Corporate updates combined with fiscal year financial results represent major strategic and performance disclosures that can significantly alter investor sentiment and company trajectory.

Annovis Bio, Inc. (ANVS) announced two presentations at the AD/PD™ 2026 International Conference. Conference presentations on core AD/PD programs signal advancing data visibility, moderately influencing investor sentiment and competitive positioning.

Annovis Bio, Inc. has received approval from the Data Safety Monitoring Board (DSMB) to proceed with its pivotal Phase 3 trial of Buntanetap for the treatment of Alzheimer’s disease. This approval marks a significant step in the development of the drug, which aims to address the unmet needs in Alzheimer’s treatment. The trial is expected to provide critical data on the efficacy and safety of Buntanetap, potentially influencing future treatment options for patients. The DSMB approval is a significant milestone that could greatly impact the company's future performance and investor sentiment regarding its Alzheimer's treatment.

Annovis Bio, Inc. has announced an open-label extension study for patients with Parkinson's disease, aiming to evaluate the long-term effects of its investigational drug, ANVS401. This study follows positive results from previous trials, where the drug demonstrated potential benefits in cognitive and motor functions. The extension study will allow participants to continue receiving treatment while providing additional data on the drug's safety and efficacy over an extended period. The company aims to enhance understanding of ANVS401's impact on Parkinson's disease management. The open-label extension study could significantly influence the company's future performance and investor sentiment regarding ANVS401's potential in treating Parkinson's disease.

Annovis Bio, Inc. (ANVS) will host a corporate update webinar on January 28, 2026, to provide insights into its business developments and future plans. The event aims to engage with investors and stakeholders, offering a platform for discussion on the company's progress and strategic direction. The webinar may influence investor sentiment and provide updates on key developments, but its overall impact on the company's trajectory is expected to be limited.

Annovis Bio, Inc. (ANVS) is set to present at the 2025 Annual Meeting of the Parkinson Study Group, highlighting its ongoing commitment to addressing Parkinson's disease through innovative research and development. Participation in a significant medical conference may enhance visibility and credibility, potentially influencing future collaborations and funding.

Annovis Bio, Inc. announced two presentations at the CTAD 2025 Conference, highlighting its ongoing research and development efforts in neurodegenerative diseases. The presentations will focus on the company's innovative approaches and potential therapeutic solutions, aiming to address significant unmet medical needs in this field. The presentations at a prominent conference could significantly enhance investor sentiment and showcase the company's strategic direction in addressing neurodegenerative diseases.

Annovis Bio, Inc. announced a meeting with the FDA to discuss its Parkinson's Disease Dementia program and reaffirmed alignment with the FDA regarding its pivotal Phase 3 Alzheimer's Disease study. This meeting is a crucial step in advancing their research and development efforts in neurodegenerative diseases. The FDA meeting could significantly impact the company's strategic direction and investor sentiment regarding its Alzheimer's and Parkinson's programs.

Annovis Bio, Inc. reported new biomarker data indicating a link between amyloid co-pathology and accelerated cognitive decline in Parkinson's patients. This finding suggests that the presence of amyloid pathology may exacerbate cognitive issues in individuals with Parkinson's disease, potentially influencing future treatment strategies and research directions in neurodegenerative diseases. The new biomarker data could significantly impact treatment approaches and research focus in Parkinson's disease, altering the company's strategic direction.

Annovis Bio, Inc. (ANVS) provided corporate updates and reported its financial results for the third quarter of 2025. The company highlighted advancements in its clinical programs and ongoing efforts to address neurodegenerative diseases. Financial results indicated changes in revenue and expenditures, reflecting the company's strategic focus on research and development. Annovis remains committed to its mission of developing innovative therapies. The financial results and corporate updates indicate moderate changes that may influence the company's operations and market perception.

Annovis Bio, Inc. has achieved significant milestones in its Phase 3 Alzheimer's program, demonstrating strong progress in clinical trials. The company reported positive results, indicating potential advancements in treatment options for Alzheimer's disease. These developments are expected to enhance Annovis's position in the biopharmaceutical market and attract investor interest. The advancements in the Phase 3 Alzheimer's program are likely to significantly impact the company's future performance and market position.

Annovis Bio, Inc. announced a registered direct offering of common stock amounting to $3.4 million, priced at-the-market under NYSE rules. The offering is intended to strengthen the company's financial position and support its ongoing clinical development efforts. The capital raise may provide necessary funding for clinical development, impacting financial performance and investor sentiment.

Annovis Bio, Inc. has successfully closed a registered direct offering of common stock, raising $6 million. The offering involved the sale of 1,500,000 shares at a price of $4.00 per share. The proceeds are intended to support the company's ongoing clinical development programs and general corporate purposes. The capital raised will support clinical development, which may influence future performance but is not expected to drastically alter the company's trajectory.

Annovis Bio, Inc. has announced a registered direct offering of common stock, raising $6 million. The offering involves the sale of approximately 1.5 million shares at a price of $4.00 per share. The company plans to use the proceeds for general corporate purposes, including funding its clinical trials and other operational expenses. The capital raised may support ongoing clinical trials and operational needs, influencing financial performance moderately.

Annovis Bio, Inc. announced novel biomarker data in Alzheimer's patients that supports the potential of its drug Buntanetap as a disease-modifying treatment. The findings suggest that Buntanetap may positively impact cognitive function and disease progression in Alzheimer's, highlighting its promise in addressing this challenging condition. The novel biomarker data indicates significant potential for Buntanetap to alter treatment approaches in Alzheimer's, which could enhance Annovis's market position and investor interest.

Annovis Bio, Inc. has appointed Mark Guerin as its new Chief Financial Officer. Guerin brings extensive experience in finance and management, having held senior positions in various biotech and pharmaceutical companies. His appointment is expected to strengthen Annovis's financial strategy and support its growth initiatives. The appointment of a new CFO may influence financial performance and operational strategy, but its overall effect is expected to be limited.